Form 4: BioMarin CFO Brian Mueller Reports Stock Transactions

Brian Mueller, EVP and CFO of BioMarin Pharmaceutical Inc., reports acquisition and disposal of company stock, including transactions under a 10b5-1 plan and the Employee Stock Purchase Plan.

Summary

• Brian Mueller, the EVP and CFO of BioMarin Pharmaceutical Inc., filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On April 30, 2024, Mueller acquired 300 shares of common stock through the Employee Stock Purchase Plan at a price of $68.646 per share.
• On May 30, 2024, Mueller exercised stock options to acquire 5,000 shares at an exercise price of $63.1 per share.
• Also on May 30, 2024, Mueller sold 5,000 shares of common stock at a price of $75.19 per share under a pre-arranged 10b5-1 trading plan.
• Following these transactions, Mueller directly owns 72,159 shares of BioMarin common stock and holds options for 0 shares from the specific stock option grant.

Sentiment

Score: 5

Explanation: Neutral sentiment. The filing simply reports transactions. The sale under a 10b5-1 plan is pre-arranged and the purchase via the employee stock purchase plan is a positive sign.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan demonstrates management's investment in the company's stock.

Negatives

• The sale of 5,000 shares, even under a 10b5-1 plan, could be perceived negatively by some investors.

Risks

• Executive stock sales, even when pre-planned, can sometimes create uncertainty among investors.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options and employee stock purchase plans.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also have executives who regularly report stock transactions via Form 4 filings.
• The use of 10b5-1 plans is a common practice among executives in these companies to manage their stock holdings while complying with insider trading regulations.

Stakeholder Impact

• Shareholders may monitor these transactions for insights into management's views on the company's stock value.
• Employees participating in the Employee Stock Purchase Plan are directly impacted by the stock price.

Key Dates